Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

History or evidence upon physical examination of CNS disease unless adequately treated (e.g., uncontrolled seizure with standard medical therapy or history of stroke)

PATIENT CHARACTERISTICS:

Pregnancy (positive serum pregnancy test) or lactation

Chronic diarrhea ≥ grade 2

Other serious illness or medical condition including any of the following:

* Unstable cardiac disease requiring treatment

* Congestive heart failure or angina pectoris even if medically controlled

* Significant arrhythmias

* History of significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent

* Active uncontrolled infection

* Severe hypercalcemia

* Other serious underlying medical condition that could impair the ability of the patient to participate in the study

* Neuropathy \> grade 1 of any etiology

Known DPD deficiency

Known severe polyneuropathy

Known allergy to Chinese hamster ovary cell proteins, other recombinant human or humanized antibodies, any excipients of bevacizumab formulation, or any other study drugs

Chronic inflammatory bowel disease

Acute or subacute intestinal occlusion

History of previous arterial thromboembolism

Uncontrolled hypertension

Evidence of bleeding diathesis or coagulopathy

Serious nonhealing wound, ulcer, or bone fracture

History of tumor other than basocellular carcinoma of the skin

Peripheral neuropathy \> grade 1 of any origin (e.g., alcohol)

Significant traumatic injury within 28 days prior to study treatment

PRIOR CONCURRENT THERAPY:

No prior chemotherapy for metastatic disease

* Prior adjuvant chemotherapy permitted if interval since last treatment administration and recurrence is \> 6 months

Major surgical procedure or open biopsy within 28 days prior to study treatment or anticipation of the need for major surgical procedure during the course of the study

Treatment in a clinical trial within 30 days prior to study entry

Concurrent treatment with other experimental drugs or other anticancer therapy

Current or recent use (within 10 days prior to study treatment) of full-dose oral or parenteral anticoagulants for therapeutic purposes

Chronic daily treatment with aspirin (\> 325 mg/day)

What this study is about